Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) announced updated results from its Phase IIIb/IV clinical trial for Adynovate (antihemophilic factor [recombinant], PEGylated) at the 27th Annual International Society on Thrombosis and Hemostasis Congress (ISTH), in Melbourne, Australia.
The PROPEL study is a PROspective, randomized, multi-center study comparing the safety and efficacy of Adynovate following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough activity Levels in subjects with severe hemophilia A.
The latest results of the landmark PROPEL study show that Adynovate prophylaxis in severe hemophilia A patients may enhance a patient’s PK profile - by targeting FVIII trough levels of 8%–12% (elevated prophylaxis arm, ELE) as compared with 1%–3% (reference prophylaxis arm, REF). This represents a clinically-meaningful trend towards more patients experiencing zero bleeds [62% ELE versus 42% REF, respectively; p=0.0545].Patients randomized to the 8%-12% target group also saw a:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze